-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The cytocytic virus (CMV) is a ubiquitous virus that infects people all over the world.
cmV is known to trigger plateroid reduction, but this association may not be adequately studied because healthy adults are usually asymptomatic or cause only mild symptoms after infection with CMV.
a recent study published in British Journal of Haematology, the authoritative journal of blood system diseases, researchers conducted a systematic review of the literature and retrieved 23 documents that covered 25 patients.
at all hematology centers in Israel, researchers searched adult patients with normal immune function with CMV-related plateboard reduction and found five new cases.
30 patients had a mid-range age of 33 (range 18-80), 73% of men, 77% had CMV-related symptoms, 48% of spleen swelling, 95% of non-typical lymphocytes in the outer blood, and 68% of patients with elevated transaminase levels.
the first-line steroid hormone therapy was only 31%, while the remission rate was 82% in 11 patients treated with anti-CMV drugs.
, four patients were treated with plateboard-producing receptoper agonists (TPO-RA), of which three (75%) responded to the treatment.
, these unique characteristics of patients with plate plateroid reduction alert medical staff that CMV infection may be the cause.
although less than one-third of cases are effective in steroid therapy, anti-CMV therapy and TPO-RA have better efficacy, suggesting that these drugs should be used earlier.
.
